Synchronous Oligometastasis and Oligoprogression as a Prognostic Marker in Patients With Extensive-Stage SCLC Treated With a Combination of Immune-Checkpoint Inhibitor and Chemotherapy (HOT2301)

Kana Hashimoto, MD; Daisuke Morinaga, MD; Hajime Asahina, MD, PhD; Mina Ishidoya, MD; Hajime Kikuchi, MD, PhD; Hiroshi Yokouchi, MD, PhD; Toshiyuki Harada, MD, PhD; Osamu Honjo, MD; Ryota Shigaki, MD; Taichi Takashina, MD, PhD; Yuka Fujita, MD, PhD; Mamoru Takahashi, MD, PhD; Yasutaka Kawai, MD; Ryotaro Kida, MD; Kenichiro Ito, MD; Noriaki Sukoh, MD, PhD; Ayumu Takahashi, MD, PhD; Fumihiro Hommura, MD, PhD; Yoshihito Ohhara, MD, PhD; Megumi Furuta, MD, PhD; Satoshi Konno, MD, PhD; Yukio Hosomi, MD, PhD; Satoshi Oizumi, MD, PhD

JTO Clinical and Research Reports (Nov 2024)

Synchronous Oligometastasis and Oligoprogression as a Prognostic Marker in Patients With Extensive-Stage SCLC Treated With a Combination of Immune-Checkpoint Inhibitor and Chemotherapy (HOT2301)

Kana Hashimoto, MD,
Daisuke Morinaga, MD,
Hajime Asahina, MD, PhD,
Mina Ishidoya, MD,
Hajime Kikuchi, MD, PhD,
Hiroshi Yokouchi, MD, PhD,
Toshiyuki Harada, MD, PhD,
Osamu Honjo, MD,
Ryota Shigaki, MD,
Taichi Takashina, MD, PhD,
Yuka Fujita, MD, PhD,
Mamoru Takahashi, MD, PhD,
Yasutaka Kawai, MD,
Ryotaro Kida, MD,
Kenichiro Ito, MD,
Noriaki Sukoh, MD, PhD,
Ayumu Takahashi, MD, PhD,
Fumihiro Hommura, MD, PhD,
Yoshihito Ohhara, MD, PhD,
Megumi Furuta, MD, PhD,
Satoshi Konno, MD, PhD,
Yukio Hosomi, MD, PhD,
Satoshi Oizumi, MD, PhD

Affiliations

Kana Hashimoto, MD: Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan
Daisuke Morinaga, MD: Department of Respiratory Medicine, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan
Hajime Asahina, MD, PhD: Department of Respiratory Medicine, NHO Hokkaido Cancer Center, Sapporo, Japan; Corresponding author. Address for correspondence: Hajime Asahina, MD, PhD, Department of Respiratory Medicine, National Hospital Organization Hokkaido Cancer Center, Sapporo, Japan.
Mina Ishidoya, MD: Department of Respiratory Medicine, Hirosaki University, Graduate School of Medicine, Hirosaki, Japan; Department of Respiratory Medicine, Aomori Prefectural Central Hospital, Aomori, Japan
Hajime Kikuchi, MD, PhD: Department of Respiratory Medicine, Obihiro-Kosei General Hospital, Obihiro, Japan
Hiroshi Yokouchi, MD, PhD: Department of Respiratory Medicine, NHO Hokkaido Cancer Center, Sapporo, Japan
Toshiyuki Harada, MD, PhD: Department of Respiratory Medicine, JCHO Hokkaido Hospital, Sapporo, Japan
Osamu Honjo, MD: Department of Respiratory Medicine, Sapporo Minami-Sanjo Hospital, Sapporo, Japan
Ryota Shigaki, MD: Department of Internal Medicine, Division of Respiratory Medicine and Neurology, Asahikawa Medical University, Asahikawa, Hokkaido, Japan
Taichi Takashina, MD, PhD: Department of Respiratory Medicine, Iwamizawa Municipal General Hospital, Iwamizawa, Japan
Yuka Fujita, MD, PhD: Department of Respiratory Medicine, NHO Asahikawa Medical Center, Asahikawa, Japan
Mamoru Takahashi, MD, PhD: Department of Respiratory Medicine and Allergology, Sapporo Medical University School of Medicine, Sapporo, Japan
Yasutaka Kawai, MD: Department of Respiratory Medicine, Oji General Hospital, Tomakomai, Japan
Ryotaro Kida, MD: Department of Respiratory Medicine, Hokkaido Prefectural Kitami Hospital, Kitami, Japan
Kenichiro Ito, MD: Department of Respiratory Medicine, KKR Sapporo Medical Center, Sapporo, Japan
Noriaki Sukoh, MD, PhD: Department of Respiratory Medicine, NHO Hokkaido Medical Center, Sapporo, Japan
Ayumu Takahashi, MD, PhD: Department of Medicine, Hokkaido Chuo Rosai Hospital, Japan Organization of Occupational Health and Safety, Iwamizawa, Japan
Fumihiro Hommura, MD, PhD: Department of Respiratory Medicine, Sapporo City General Hospital, Sapporo, Japan
Yoshihito Ohhara, MD, PhD: Department of Medical Oncology, Hokkaido University Hospital, Hokkaido, Japan
Megumi Furuta, MD, PhD: Department of Respiratory Medicine, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan
Satoshi Konno, MD, PhD: Department of Respiratory Medicine, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan
Yukio Hosomi, MD, PhD: Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan
Satoshi Oizumi, MD, PhD: Department of Respiratory Medicine, NHO Hokkaido Cancer Center, Sapporo, Japan

Journal volume & issue: Vol. 5, no. 11
p. 100715

Abstract

Read online

Introduction: Oligometastasis and oligoprogression (OP) has not been adequately defined in extensive-stage SCLC (ES-SCLC) and may be a good indication for adding local treatment. Therefore, this multicenter study aimed to investigate the prognostic impact of oligometastasis and OP in ES-SCLC. Methods: We enrolled patients who received chemoimmunotherapy between September 2019 and June 2022. Patients were classified into oligometastasis and non-oligometastasis groups by determining the number of original tumor lesions and distant metastases (worsening or newly appearing lesions) at the time of initial diagnosis and disease progression after first-line treatment. Results: We retrospectively analyzed 265 consecutive patients with ES-SCLC. Synchronous oligometastasis (SOM) and OP was defined as less than or equal to five lesions in less than or equal to two organs, including lungs; 21.0% and 53.2% of patients had SOM and OP, respectively. Median progression-free survival was 5.8 months and 4.9 months in patients with and without SOM, respectively (hazard ratio [HR] = 0.72, 95% confidence interval [CI]: 0.51–1.02, p = 0.065). Median overall survival was 20.5 months and 15.0 months in patients with and without SOM (HR = 0.58, 95% CI: 0.37–0.95, p = 0.027) from the initiation of first-line treatment. The OP group revealed a better progression-free survival of 5.2 months (versus 3.2 mo, HR = 0.69, 95% CI: 0.50–0.96, p = 0.026) and overall survival of 15.1 months (versus 7.5 mo, HR = 0.44, 95% CI: 0.29–0.66, p = 0.027) from the initiation of second-line treatment compared with the non-OP group. The Lung Immune Prognostic Index score was significantly lower in the SOM and OP group. Conclusions: ES-SCLC in patients with SOM and OP may be more indolent than that of the nonoligometastasis group, therefore, new treatment strategies, including the addition of local treatment, should be explored. Clinical trial registration: This study was registered at UMIN-CTR (UMIN000053402).

Published in JTO Clinical and Research Reports

ISSN: 2666-3643 (Online)
Publisher: Elsevier
Country of publisher: United States
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://www.journals.elsevier.com/jto-clinical-and-research-reports/

About the journal

Abstract

Keywords